Provenge (sipuleucel-T) / Bausch Health 
Welcome,         Profile    Billing    Logout  
 10 Diseases   5 Trials   5 Trials   1130 News 


12345678910111213»
  • ||||||||||  Clinical, Journal:  The role of immunotherapy in urological cancers. (Pubmed Central) -  May 31, 2024   
    Considering ongoing randomized clinical trials, immunotherapeutic agents promise to transform the uro-oncology field significantly. In this review, we aimed to summarize the role of immunotherapy in urothelial, renal and prostate cancer in the light of randomized clinical trials.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, Provenge (sipuleucel-T) / Bausch Health
    Review, Journal:  Advances and prospects of mRNA vaccines in cancer immunotherapy. (Pubmed Central) -  Jan 4, 2024   
    We expect a rapid development of mRNA vaccines for cancer immunotherapy in the near future. This review provides a brief overview of the current status of mRNA vaccines, highlights the action mechanism of cancer mRNA vaccines, their recent advances in clinical trials, and prospects for their clinical applications.
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Journal, Metastases:  Racial disparity in the utilization of immunotherapy for advanced prostate cancer. (Pubmed Central) -  Oct 30, 2023   
    Black patients comparatively did not exhibit increased utilization of this novel agent after 2010. Further studies are necessary to help understand barriers to access to new treatment in mCRPC and eliminate the burden of disease in minority populations.".
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Review, Journal, IO biomarker, Metastases:  A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer. (Pubmed Central) -  Oct 16, 2023   
    Since regulatory approval of the vaccine therapy sipuleucel-T in the biomarker-unselected population, there has not been much success with immunotherapy treatment in advanced prostate cancer...On the horizon, novel drugs using bispecific T-cell engager (BiTE) and chimeric antigen receptors (CAR) technology are being explored and have shown promising early efficacy in this disease. Here we discuss the features of the tumour microenvironment that predispose to immune resistance and rational strategies to enhance antitumour responsiveness in advanced prostate cancer.
  • ||||||||||  Xofigo (radium Ra-223 dichloride) / Bayer
    Utilization of high-cost prostate cancer therapies by oncologists in the merit-based incentive payment system (MIPS). (3rd Floor, Back Bay Hall; Poster Bd #: C26) -  Oct 13, 2023 - Abstract #ASCOQC2023ASCO_QC_151;    
    Our findings suggest that the MIPS program may be ineffective at measuring and incentivizing high value care among oncologists. Specialty-specific recalibration of cost and quality measures is needed to ensure that policy efforts to promote value-based care do not compromise healthcare quality and outcomes.
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Review, Journal:  Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. (Pubmed Central) -  Sep 12, 2023   
    Despite the success of the first generation of DC-based vaccines, represented by the first FDA-approved DC-based therapeutic cancer vaccine Provenge, several challenges remain unsolved...This review addresses the limitations of the currently most adopted classical DC vaccine and evaluates new generations of DC vaccines in detail, including biomaterial-based, immunogenic cell death-inducing, mRNA-pulsed, DC small extracellular vesicle (sEV)-based, and tumor sEV-based DC vaccines. These innovative DC vaccines are envisioned to provide a significant breakthrough in cancer immunotherapy landscape and are expected to be supported by further preclinical and clinical studies.
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Trial initiation date, Trial primary completion date, Metastases:  Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (clinicaltrials.gov) -  Aug 9, 2023   
    P1,  N=12, Not yet recruiting, 
    These innovative DC vaccines are envisioned to provide a significant breakthrough in cancer immunotherapy landscape and are expected to be supported by further preclinical and clinical studies. Initiation date: Jun 2023 --> Sep 2023 | Trial primary completion date: Dec 2024 --> Mar 2024
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, Provenge (sipuleucel-T) / Bausch Health
    Journal:  Vaccinating against cancer: getting to prime time. (Pubmed Central) -  Jun 11, 2023   
    These represent the two approaches that have the most traction: vaccinating against cognate antigen and priming responses using tumors in situ. Here, we review the challenges and opportunities researchers face in developing therapeutic vaccines for cancer.
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health, Verzenio (abemaciclib) / Eli Lilly
    MODULE 3: Available and Emerging Strategies for Newly Diagnosed Metastatic CRPC (mCRPC) (Hilton Chicago; Grand Ballroom (Level 2)) -  May 26, 2023 - Abstract #ASCO2023ASCO_7057;    
    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi. Key clinical and biological factors in the selection of therapy for newly diagnosed mCRPC; influence of earlier use of secondary hormonal therapy and chemotherapy on current management approaches Key findings from clinical trial and real-world data sets exploring the efficacy and safety of sipuleucel-T Optimal patient selection for treatment with sipuleucel-T; importance of early identification of appropriate candidates Data sets defining the role of secondary hormonal therapies for patients with mCRPC, including those who have received one of these agents in an earlier disease setting Role of the CDK4/6 pathway in prostate cancer proliferation and resistance to androgen receptor (AR)-targeted therapy Available efficacy and safety findings with CDK4/6 inhibitors for mCRPC Design, eligibility criteria and primary and secondary endpoints of the Phase II/III CYCLONE 2 trial evaluating first-line abiraterone and prednisone with or without abemaciclib for mCRPC
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Journal:  Emerging treatment options for prostate cancer. (Pubmed Central) -  Apr 27, 2023   
    Treatment landscape for metastatic castrate-resistant prostate cancer (mCRPC) has evolved beyond additional agents with ARPI and/or docetaxel, including other treatments with sipuleucel-T, radium, cabazitaxel, PARP inhibitors, and lutetium, which have specific indications and role in sequencing. Novel therapies remain critically needed after progression from lutetium.
  • ||||||||||  HB-300 / Hookipa Pharma
    HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer. (On Demand | Hall A; Poster Bd # 197a) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_1676;    
    P1/2
    18; documented mCRPC (adenocarcinoma without neuroendocrine or small cell features); receipt of at least 1 androgen deprivation therapy and no prior chemotherapy regimens (docetaxel in the castration-sensitive setting is allowed); ?1 measurable lesion; ECOG PS 0-1...Clinical trial# NCT05553639. Clinical trial information: NCT05553639.
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Journal, Metastases:  Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. (Pubmed Central) -  Apr 14, 2023   
    OOP payments were lower than gross drug payments; mean 6-month OOP payments were highest for cabazitaxel ($1,044 USD) and lowest for docetaxel ($296 USD)...OOP payments among patients with employer-sponsored health insurance are much lower than gross drug payments, and they vary both across and within first-line drug types, with some patients making very high OOP payments. Although lowering drug prices would reduce pharmaceutical spending for patients with mCRPC, decreasing patient financial burden requires understanding an individual patient's benefit design.
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Journal:  Advances in cancer vaccines for immunotherapy of prostate cancer. (Pubmed Central) -  Mar 24, 2023   
    However, due to its own limitations, Sipuleucel-T has not been widely adopted. Meanwhile, owing to the complexity of immunotherapy and the specificity of prostate cancer, the remaining prostate cancer vaccines have not shown good clinical benefit in large randomized phase II and phase III trials, and further in-depth studies are still needed.
  • ||||||||||  Journal, BRCA Biomarker, PARP Biomarker, IO biomarker:  Prostate cancer and novel pharmacological treatment options - what's new for 2022? (Pubmed Central) -  Mar 14, 2023   
    Several therapeutic options are available for pretreated patients: cabazitaxel, olaparib, and rucaparib for BRCA mutations, Radium-223 for selected patients with symptomatic bone metastasis, sipuleucel T, and 177 LuPSMA-617...The radionuclide Lu-PSMA-617 proved successful outcomes in pretreated mCRPC patients. Additional studies will better clarify the appropriate candidates to each strategy and the correct treatments' sequence.
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health
    Review, Journal:  Vaccines as treatments for prostate cancer. (Pubmed Central) -  Mar 7, 2023   
    Limitations include hampered comparability between studies due to heterogeneity in study designs (e.g., measuring, quantifying, and reporting HSUVs) and treatments assessed. Overall, five approaches have been assessed in randomized phase III trials and sipuleucel-T was approved as a treatment for metastatic
  • ||||||||||  Provenge (sipuleucel-T) / Bausch Health, Verzenio (abemaciclib) / Eli Lilly
    MODULE 3: Current Therapeutic Options for Patients with Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) (San Francisco Marriott Marquis, Yerba Buena ) -  Feb 2, 2023 - Abstract #ASCOGU2023ASCO_GU_922;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Merck, and Sanofi. Key clinical and biologic factors in the selection of therapy for patients with newly diagnosed mCRPC; impact of earlier use of secondary hormonal therapy and chemotherapy on current disease management approaches Key findings from clinical trial and real-world data sets exploring the efficacy and safety of sipuleucel-T; impact of patient age, race, PSA level and other factors on outcomes Optimal patient selection for sipuleucel-T; importance of early identification of candidates Biologic basis for combining PARP inhibitors with antiandrogen therapies for prostate cancer; rationale for the potential activity of these combinations in patients without homologous recombination repair (HRR) gene mutations Available and emerging data (eg, from the PROpel, MAGNITUDE and TALAPRO-2 trials) with PARP inhibitors combined with secondary hormonal agents for previously untreated mCRPC Rationale for the evaluation of CDK4/6 inhibitors among patients with mCRPC Design, eligibility criteria and primary and secondary endpoints of the Phase II/III CYCLONE 2 trial evaluating first-line abiraterone and prednisone with or without abemaciclib for mCRPC; estimated completion date
  • ||||||||||  Xofigo (radium Ra-223 dichloride) / Bayer
    Review, Journal:  Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. (Pubmed Central) -  Jan 22, 2023   
    Contrarily, immune-based treatments have generally demonstrated little activity in advanced prostate cancer, with the exception of the autologous cellular vaccine, sipuleucel-T...The ability of radiation therapy to not only eradicate tumor cells but also potentially other immune-regulatory cells within the tumor immune microenvironment suggests that targeted radionuclide therapies may be well poised to combine with immune-targeted therapies to eliminate prostate cancer metastases more effectively. This review provides an overview of the recent advances of targeted radiation agents currently approved for prostate cancer, and those being investigated in combination with immunotherapy, and discusses the challenges as well as the opportunities in this field.